S&P 500   5,117.73 (-1.56%)
DOW   37,937.74 (-1.36%)
QQQ   438.43 (-1.56%)
AAPL   175.80 (+0.43%)
MSFT   422.04 (-1.38%)
META   512.43 (-2.05%)
GOOGL   157.62 (-1.12%)
AMZN   185.80 (-1.72%)
TSLA   171.64 (-1.70%)
NVDA   885.41 (-2.29%)
AMD   163.30 (-4.22%)
NIO   4.14 (-7.17%)
BABA   71.88 (-3.97%)
T   16.36 (-0.37%)
F   12.59 (-3.45%)
MU   122.68 (-3.79%)
GE   154.60 (-1.78%)
CGC   7.77 (-4.66%)
DIS   114.38 (-2.36%)
AMC   2.66 (-5.00%)
PFE   26.01 (-1.25%)
PYPL   64.42 (-2.10%)
XOM   121.04 (-0.62%)
S&P 500   5,117.73 (-1.56%)
DOW   37,937.74 (-1.36%)
QQQ   438.43 (-1.56%)
AAPL   175.80 (+0.43%)
MSFT   422.04 (-1.38%)
META   512.43 (-2.05%)
GOOGL   157.62 (-1.12%)
AMZN   185.80 (-1.72%)
TSLA   171.64 (-1.70%)
NVDA   885.41 (-2.29%)
AMD   163.30 (-4.22%)
NIO   4.14 (-7.17%)
BABA   71.88 (-3.97%)
T   16.36 (-0.37%)
F   12.59 (-3.45%)
MU   122.68 (-3.79%)
GE   154.60 (-1.78%)
CGC   7.77 (-4.66%)
DIS   114.38 (-2.36%)
AMC   2.66 (-5.00%)
PFE   26.01 (-1.25%)
PYPL   64.42 (-2.10%)
XOM   121.04 (-0.62%)
S&P 500   5,117.73 (-1.56%)
DOW   37,937.74 (-1.36%)
QQQ   438.43 (-1.56%)
AAPL   175.80 (+0.43%)
MSFT   422.04 (-1.38%)
META   512.43 (-2.05%)
GOOGL   157.62 (-1.12%)
AMZN   185.80 (-1.72%)
TSLA   171.64 (-1.70%)
NVDA   885.41 (-2.29%)
AMD   163.30 (-4.22%)
NIO   4.14 (-7.17%)
BABA   71.88 (-3.97%)
T   16.36 (-0.37%)
F   12.59 (-3.45%)
MU   122.68 (-3.79%)
GE   154.60 (-1.78%)
CGC   7.77 (-4.66%)
DIS   114.38 (-2.36%)
AMC   2.66 (-5.00%)
PFE   26.01 (-1.25%)
PYPL   64.42 (-2.10%)
XOM   121.04 (-0.62%)
S&P 500   5,117.73 (-1.56%)
DOW   37,937.74 (-1.36%)
QQQ   438.43 (-1.56%)
AAPL   175.80 (+0.43%)
MSFT   422.04 (-1.38%)
META   512.43 (-2.05%)
GOOGL   157.62 (-1.12%)
AMZN   185.80 (-1.72%)
TSLA   171.64 (-1.70%)
NVDA   885.41 (-2.29%)
AMD   163.30 (-4.22%)
NIO   4.14 (-7.17%)
BABA   71.88 (-3.97%)
T   16.36 (-0.37%)
F   12.59 (-3.45%)
MU   122.68 (-3.79%)
GE   154.60 (-1.78%)
CGC   7.77 (-4.66%)
DIS   114.38 (-2.36%)
AMC   2.66 (-5.00%)
PFE   26.01 (-1.25%)
PYPL   64.42 (-2.10%)
XOM   121.04 (-0.62%)
NASDAQ:TMDX

TransMedics Group (TMDX) Stock Price, News & Analysis

$91.78
-2.17 (-2.31%)
(As of 02:22 PM ET)
Today's Range
$90.75
$94.07
50-Day Range
$70.86
$95.65
52-Week Range
$36.42
$99.63
Volume
374,941 shs
Average Volume
677,218 shs
Market Capitalization
$3.00 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$102.00

TransMedics Group MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
9.8% Upside
$102.00 Price Target
Short Interest
Bearish
18.31% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.76mentions of TransMedics Group in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$9.47 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.14) to $0.41 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.53 out of 5 stars

Medical Sector

2650th out of 2,784 stocks

Electromedical Equipment Industry

49th out of 54 stocks

TMDX stock logo

About TransMedics Group Stock (NASDAQ:TMDX)

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

TMDX Stock Price History

TMDX Stock News Headlines

SHOCKING Altcoin Moves…
Bitcoin's recent price boom has sent select altcoins into an absolute FRENZY! Which is why we've gathered 27 crypto experts to share their top picks and predictions as we rapidly approach the Bitcoin halving event this month…
SHOCKING Altcoin Moves…
Bitcoin's recent price boom has sent select altcoins into an absolute FRENZY! Which is why we've gathered 27 crypto experts to share their top picks and predictions as we rapidly approach the Bitcoin halving event this month…
TransMedics: Strong Business, Fully Valued Stock
TMDX Jul 2024 135.000 call
Cracking The Code: Understanding Analyst Reviews For TransMedics Gr
See More Headlines
Receive TMDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/26/2024
Today
4/12/2024
Next Earnings (Estimated)
5/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:TMDX
Fax
N/A
Employees
584
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$102.00
High Stock Price Target
$110.00
Low Stock Price Target
$95.00
Potential Upside/Downside
+8.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-25,030,000.00
Pretax Margin
-11.04%

Debt

Sales & Book Value

Annual Sales
$241.62 million
Cash Flow
$0.14 per share
Book Value
$4.20 per share

Miscellaneous

Free Float
30,521,000
Market Cap
$3.07 billion
Optionable
Optionable
Beta
1.99
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives


TMDX Stock Analysis - Frequently Asked Questions

Should I buy or sell TransMedics Group stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TMDX shares.
View TMDX analyst ratings
or view top-rated stocks.

What is TransMedics Group's stock price target for 2024?

7 equities research analysts have issued twelve-month price targets for TransMedics Group's stock. Their TMDX share price targets range from $95.00 to $110.00. On average, they expect the company's share price to reach $102.00 in the next twelve months. This suggests a possible upside of 9.8% from the stock's current price.
View analysts price targets for TMDX
or view top-rated stocks among Wall Street analysts.

How have TMDX shares performed in 2024?

TransMedics Group's stock was trading at $78.93 at the beginning of the year. Since then, TMDX shares have increased by 17.7% and is now trading at $92.91.
View the best growth stocks for 2024 here
.

When is TransMedics Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our TMDX earnings forecast
.

How were TransMedics Group's earnings last quarter?

TransMedics Group, Inc. (NASDAQ:TMDX) announced its quarterly earnings results on Monday, February, 26th. The company reported $0.12 earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.22. The firm had revenue of $81.20 million for the quarter, compared to analysts' expectations of $68.49 million. TransMedics Group had a negative net margin of 10.36% and a negative trailing twelve-month return on equity of 2.35%. The firm's revenue was up 158.6% on a year-over-year basis. During the same period last year, the company posted ($0.21) earnings per share.

What guidance has TransMedics Group issued on next quarter's earnings?

TransMedics Group updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $360.0 million-$370.0 million, compared to the consensus revenue estimate of $330.2 million.

What is Waleed Hassanein's approval rating as TransMedics Group's CEO?

17 employees have rated TransMedics Group Chief Executive Officer Waleed Hassanein on Glassdoor.com. Waleed Hassanein has an approval rating of 83% among the company's employees.

What other stocks do shareholders of TransMedics Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), RTX (RTX), Yamana Gold (AUY), B2Gold (BTG), Beyond Meat (BYND) and Walt Disney (DIS).

When did TransMedics Group IPO?

TransMedics Group (TMDX) raised $75 million in an initial public offering (IPO) on Thursday, May 2nd 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

Who are TransMedics Group's major shareholders?

TransMedics Group's stock is owned by a number of institutional and retail investors. Top institutional investors include Park Avenue Securities LLC (0.03%) and Los Angeles Capital Management LLC (0.02%). Insiders that own company stock include David Weill, Edward M Basile, Edwin M Kania Jr, James R Tobin, John F Carey, Laura Damme, Miriam Provost, Stephanie Lovell, Stephen Gordon, Tamer I Khayal, Tamer I Khayal and Waleed H Hassanein.
View institutional ownership trends
.

How do I buy shares of TransMedics Group?

Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TMDX) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners